It looks like you're using an Ad Blocker.
Please white-list or disable AboveTopSecret.com in your ad-blocking tool.
Some features of ATS will be disabled while you continue to use an ad-blocker.
Despite BSdoc's insistence, healthcare is international Big Business, inextricably intertwined with other international Big Businesses - and decisions are taken to maximize profits, not to benefit mankind. It is the law that corporations must put profits first, before any and all other considerations.
Originally posted by JoJo the religious man
Yes we can now go back to topic! I am not sure how we started arguing about healthcare systems, but as long as its over.
...Anyways... reasearchers found an enzyme (I think thats how you spell it) that is found in 90% of the different types of cancer cells it had a name but I forgot what it was so if anyone else heard about this story I don't care through what news station would they please inform me what the name of the enzyme is? Anyway they said that now that they know this they start to work on a cure to target the cancer cells enzyme and kill it without letting the cancer spread (even though they said it would take years of study on the enzyme and cancer patients). This is good news isn't it?!
Findings Support Study Of Telomerase As Potential Single, Specific Anti-Cancer Target
MENLO PARK, CA — December 23, 1994 — An "immortalizing enzyme" known as telomerase is active in many different kinds of cancers and cancer cell lines, but is not found in the normal tissues from which those cancers arose, according to a study published today in Science by researchers from The University of Texas Southwestern Medical Center at Dallas and Geron Corp.
These results confirm and extend earlier studies suggesting that telomerase might be a specific and universal marker for cancer with potential as a target for anti-tumor diagnostics and therapeutics.
"IMMORTALIZING ENZYME" DETECTED IN MANY TYPES OF CANCER
Incorporated in the state of Delaware in 1990, Geron has been in business since 1992. The Company’s headquarters and main facilities are located in Menlo Park, California. The Company also has a subsidiary in Edinburgh, Scotland.
Geron is a biopharmaceutical company developing and commercializing three groups of products:
1. therapeutic products for oncology (cancer) that target telomerase;
2. pharmaceuticals that activate telomerase in tissues impacted by senescence, injury or degenerative disease; and
3. cell-based therapies derived from its human embryonic stem cell platform for applications in multiple chronic diseases
Telomerase is an enzyme that is expressed in nearly all cancer cells, but not in most normal cells. We hope to kill cancer cells in which telomerase is abnormally expressed by inhibiting or targeting telomerase, and to diagnose cancer by measuring telomerase activity. We are also working to develop product candidates to treat various degenerative diseases by the controlled activation of telomerase.
Human embryonic stem cells can develop and differentiate into all cells and tissues in the body. As such, they are a potential source for the manufacture of replacement cells and tissues for organ repair applications in chronic diseases.
Cancer is a group of diseases characterized by the uncontrolled growth and spread of abnormal cells. The American Cancer Society estimates that approximately 1.4 million new cancer cases will be diagnosed in the year 2005. Overall annual costs associated with cancer in 2004 were $189.8 billion in the United States alone. Because telomerase is detectable in more than 30 human cancer types and in the great majority of cancer samples studied, we believe that telomerase-based drugs could overcome the limitations of current cancer therapies and potentially be broadly applicable and highly specific drug treatments for cancer.
We, our collaborators and our licensees, are developing a range of anti-cancer therapies based on telomerase inhibitors, telomerase therapeutic vaccines and telomerase-based oncolytic (cancer-killing) viruses, and diagnostics based on telomerase detection. We believe telomerase is an ideal target for cancer therapeutics and diagnostics because it appears to be both universal—it is expressed in all major types of cancers studied to date—and specific—it is not expressed in most normal cells. We believe that we have the dominant patent position in the field of telomerase. Whether it is achieved by us or by our collaborators and licensees, we believe that progress in the development of any of these telomerase-based cancer therapeutics will further validate the importance of telomerase as a cancer target and therefore benefit all of our telomerase cancer programs.
The goal of therapeutic cancer vaccines is to “teach” the patient’s own immune system to attack cancer cells while sparing other cells. This is done by exposing the immune system to a substance (antigen) that is specific to cancer cells, inducing an immune response to any cells that present that antigen. We believe that telomerase’s characteristics make it an ideal antigen for cancer vaccines.
...In 2004, we acquired rights from Argos Therapeutics, Inc. (formerly Merix) to commercialize the ex vivo dendritic cell processing technology used in the Duke clinical trial for telomerase and any other defined tumor-specific antigens. We own the rights to the telomerase antigen and its use in therapeutic vaccines. We have also granted a non-exclusive license to Dendreon Corporation to develop an ex vivo telomerase vaccine using Dendreon’s antigen-presenting system.
In 2005, we entered into a collaboration and license agreement with Merck & Co., Inc. to develop a cancer vaccine targeting telomerase utilizing Merck's expertise in vaccine technologies. Geron and Merck have jointly developed a research and development plan to optimize and expedite the demonstration of efficacy and tolerability of a potential vaccine against telomerase using Merck's platform. Meanwhile, Geron will continue to develop its dendritic cell-based vaccine described above.
Poison For Profit
The huge transnational companies that produce toxic chemicals found in pesticides, herbicides and industrial and household products profit not only from the sale of these products, but also from the symptoms and chronic illnesses that they can trigger. ...The vast majority of chemicals found in pesticides and other products, undergo little or no testing for chronic, low level exposures and for chronic health effects. ...The same chemical companies that produce toxic chemicals also produce prescription drugs, veterinary medicines, a wide array of medical products and imaging technologies, hold cancer treatment and medical device patents, and a produce a staggering assortment of over-the-counter palliatives.
Families with toxin induced illnesses often spend large sums for drugs and medical treatment. ...This circle of profit is not conspiracy theory, but an easily provable fact.
Below are chem/pharm web sites for the largest companies in the world. There you can see quickly and clearly that these companies profit from all sides of the picture.
The combination of pharmaceuticals and agribusiness--often with a large dose of biotechnology--seemed like a good strategic fit. ...Rampant consolidation in agrochemicals and pharmaceuticals makes it difficult to compete with less than world-scale businesses. Troubles in the agricultural biotechnology area may add to the desire to put some distance between different business units. And many claim that the anticipated R&D synergies did not materialize.
"Life sciences companies"--maybe without the moniker, but with the requisite businesses--had existed for many years. Major drug firms--including Eli Lilly & Co., American Home Products (AHP), Abbott Laboratories, and Merck--had long held agricultural, and even some chemical, operations, along with their better known pharmaceuticals. But the life sciences label didn't come into vogue until 1993, when ICI split off its agrochemicals, drugs, and specialty chemicals units to create Zeneca. ...Three years later, Sandoz and Ciba-Geigy split off their chemical operations and put the remaining drug and ag units together as the life sciences company Novartis. In 1997, Monsanto moved its chemical businesses into Solutia and became a life sciences company, fulfilling then-chief executive officer Robert Shapiro's vision. ..."We're creating a new kind of company dedicated to meeting growing global needs for nutrition and health," he said at the time. "This will be a fast-moving, technology-driven, intensely competitive global business." Shapiro subsequently spent $6 billion or more on agbiotech and seed company acquisitions.
Starting in 1997, DuPont began a widely publicized life sciences buying spree to create a platform for growth. It spent $13.5 billion in cash and stock to buy seed producer Pioneer Hi-Bred, soy processor Protein Technologies, and Merck's 50% stake in DuPont Merck Pharmaceutical. Dow Chemical, meanwhile, was building up its agrochemical and agbiotech businesses. Hoechst and Rhône-Poulenc quickly followed suit by creating the chemical companies Celanese and Rhodia, respectively, and merging their remaining operations as Aventis in December 1999. A few years before, Hoechst had spent about $11 billion to build up its drugs and agriculture businesses, while Rhône-Poulenc spent about $7 billion on drug buys. Aventis was hailed as the "new world leader in life sciences, holding top position.
BUSINESS Volume 79, NEWS ANALYSIS: LIFE SCIENCES
08 February 2006
The European Commission recently proposed a new EU Regulation concerning socalled advanced therapy medicinal products (gene therapy products, somatic cell products and tissue engineered products).1 The proposed legislation establishes specific rules concerning the authorization, supervision and pharmacovigilance of advanced therapy medicinal products. The approach is based on a single, integrated European regulatory framework for all such products. The legislation, which if adopted will be directly applicable in all 25 EU Member States, will be of importance to innovative companies active in these fields....
United States: New EU Rules Proposed For Gene, Cell And Tissue Engineered Therapies
Originally posted by bsl4doc
So...still no answer as to why a socialized government would prevent a known cure from being used, thus cutting health care costs and line their pockets instead of paying for chronic health care?
The business perspective is important - and FYI - countries with socialized medicine use the same reinsurance companies as do private insurance providers. So the rules are set internationally regarding coverage and how the industry works in terms of money flow.
Originally posted by JoJo the religious man
Yes we can now go back to topic!
I am not sure how we started arguing about healthcare systems, but as long as its over.